XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
 6 Months Ended
Jul. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended26-Weeks Ended
July 31,
2021		August 1,
2020		July 31,
2021		August 1,
2020
Stock-based compensation expense by type:
Stock options
$— $— $174 $90 
Restricted stock units1,092 587 2,880 1,647 
Employee stock purchases
24 27 108 70 
Director deferred compensation15 23 21 47 
  Total stock-based compensation expense1,131 637 3,183 1,854 
Income tax benefit recognized279 168 758 423 
  Stock-based compensation expense, net of income tax$852 $469 $2,425 $1,431 

Expense for restricted stock units is shown net of forfeitures of approximately $0.1 million and $0.7 million for the 13-weeks ended July 31, 2021 and August 1, 2020, respectively. Expense for restricted stock units is shown net of forfeitures of approximately $0.2 million and $0.9 million for the 26-weeks ended July 31, 2021 and August 1, 2020, respectively.
We have granted the following equity awards:
13-Weeks Ended26-Weeks Ended
July 31,
2021		August 1,
2020		July 31,
2021		August 1,
2020
Stock options
— — 4,384 27,000 
Restricted stock unit awards
790 3,264 62,031 337,749 
Performance-based restricted stock unit awards
— — 22,492 — 
Deferred stock units
174 1,120 258 3,263 

At July 31, 2021, the total compensation costs not yet recognized related to unvested restricted stock unit awards was $9.3 million and the weighted-average period over which such awards are expected to be recognized is 2.4 years. There were no unrecognized compensation costs related to unvested stock options at July 31, 2021.

During the 13-weeks ended July 31, 2021 and August 1, 2020, no stock options were granted. During the 26-weeks ended July 31, 2021 and August 1, 2020, 4,384 and 27,000 stock options were granted, respectively. The weighted-average grant date fair value of stock options granted during the 26-weeks ended July 31, 2021 and August 1, 2020 was $39.73 and $3.33 per share, respectively.
Under the 2012 Non-Employee Director Equity Plan ("2012 Plan"), no shares of our common stock were awarded during the 13-weeks or 26-weeks ended July 31, 2021 or August 1, 2020.
The number of shares purchased, the average price per share, and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended26-Weeks Ended
July 31,
2021		August 1,
2020		July 31,
2021		August 1,
2020
Shares purchased2,063 11,143 9,508 28,901 
Average price per share$58.56 $8.60 $43.44 $9.03 
Weighted-average fair value at grant date$11.39 $2.39 $11.44 $3.51